Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Authors: Bonaventura Clotet, Judith Feinberg, Jan van Lunzen, Marie-Aude Khuong-Josses, Andrea Antinori, Irina Magdalena Dumitru, Vadim Pokrovskiy, Jan Fehr, Roberto Ortiz, Michael S. Saag, Julia Harris, Clare Brennan, Tamio Fujiwara, Sherene Min - The Lancet 2014 cited by 501